MedPath

Effect of Fish Oil on Adiposity and Atherogenic Factors in Type 2 Diabetic Women

Not Applicable
Terminated
Conditions
Type 2 Diabetes
Registration Number
NCT00371982
Lead Sponsor
Assistance Publique - Hôpitaux de Paris
Brief Summary

1. whether the intake of n-3 PUFA has additional effects on insulin sensitivity and adiposity (total fat mass and adipocyte morphology and function) in T2D women.

2. n-3 PUFA supplementation might influence inflammatory genes expression in the adipose tissue of T2D patients.

Detailed Description

Thus, the present study was designed to evaluate the effects of n-3 PUFAs dietary supplementation on lipid and glucose homeostasis and to address the impact of this treatment on adiposity and adipose tissue gene expression in T2D women.A total of 27 T2D women (BMI 27-35kg/m², age 40-60 y) were randomly allocated to two months of 3 g/day of either fish oil (1.8 g n-3 PUFA) or placebo (paraffin oil), in a double-blind parallel design.

Recruitment & Eligibility

Status
TERMINATED
Sex
Female
Target Recruitment
24
Inclusion Criteria
  1. Type 2 diabetic postmenopausal women
  2. glycaemia of 7.87-14.0 mmol/l, HbA1c of 7 to 10.5%
  3. plasma triglycerides between 1.72-4.6 mmol/l,
  4. aged between 40 -60,
  5. BMI: 27-40 kg/m2
  6. able to swallow tablets
Read More
Exclusion Criteria
  1. patients with abnormal renal, hepatic and thyroid functions as determined by physical examination, blood cell count and standard blood biochemical profile
  2. patients with gastrointestinal disorders
  3. patients treated with thiazolidinediones or insulin
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
The effect of 2 month treatment on:
adiposity (total fat mass, adipocyte morphology), atherogenic markers and insulin sensitivity
Secondary Outcome Measures
NameTimeMethod
the underlying mechanisms of the observed results and tried to define new targets of fish oil metabolic effects
and the impact of fish oil on systemic inflammatory markers and adipose tissue inflammatory genes.

Trial Locations

Locations (1)

Department of Diabetes-Hotel Dieu Hospital

🇫🇷

Paris, France

© Copyright 2025. All Rights Reserved by MedPath